World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
150
Citations
123278
World Ranking
1136
National Ranking
654

Overview

Brian J. Druker is affiliated with Oregon Health & Science University in the United States. Their research contributions span multiple fields, focusing extensively on areas within medicine, molecular biology, and hematology.

Their primary fields of study include:

  • Physics and Astronomy
  • Earth and Planetary Sciences
  • Medicine

Within these fields, notable subfields of study they have contributed to are:

  • Astronomy and Astrophysics
  • Oceanography
  • Aerospace Engineering
  • Hematology
  • Molecular Biology

The main research topics covered by their work include:

  • Geophysics and Gravity Measurements
  • Ionosphere and Magnetosphere Dynamics
  • GNSS Positioning and Interference
  • Solar and Space Plasma Dynamics
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research

Brian J. Druker has frequently published in several venues, appearing most often in:

  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
  • Blood
  • Cell
  • Cancer Cell
  • Cancer Research

Some of the recent papers authored or co-authored by Brian J. Druker include:

  • Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma, 2020, Cell
  • Proteogenomic characterization of pancreatic ductal adenocarcinoma, 2021, Cell
  • Response and Resistance to BCR-ABL1-Targeted Therapies, 2020, Cancer Cell
  • A proteogenomic portrait of lung squamous cell carcinoma, 2021, Cell
  • Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma, 2021, Cancer Cell

The scientist maintains collaborations with several frequent co-authors including:

  • Jeffrey Tyner
  • Paul Piehowski
  • Marina Gritsenko
  • Joshua Hansen
  • Anupriya Agarwal

Best Publications

  • Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

    Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

    Brian J. Druker;Shu Tamura;Elisabeth Buchdunger;Sayuri Ohno

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

    Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

    Heikki Joensuu;Peter J. Roberts;Maarit Sarlomo-Rikala;Leif C. Andersson

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

    Elisabeth Buchdunger;Catherine L. Cioffi;Norman Law;David Stover

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative

    Elisabeth Buchdunger;Jürg Zimmermann;Helmut Mett;Thomas Meyer

  • The development of imatinib as a therapeutic agent for chronic myeloid leukemia

    Michael Deininger;Elisabeth Buchdunger;Elisabeth Buchdunger;Elisabeth Buchdunger;Brian J. Druker;Brian J. Druker;Brian J. Druker

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Thomas O'Hare;Thomas O'Hare;William C. Shakespeare;Xiaotian Zhu;Christopher A. Eide;Christopher A. Eide

  • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

    Thomas O'Hare;Denise K. Walters;Eric P. Stoffregen;Taiping Jia

  • Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

    Michael C. Heinrich;Diana J. Griffith;Brian J. Druker;Cecily L. Wait

  • Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

    Brian J. Druker;Nicholas B. Lydon

  • Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

    A. Hochhaus;S. Kreil;A. S. Corbin;P. La Rosée;P. La Rosée

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

Frequent Co-Authors

Michael W. Deininger
Michael W. Deininger University of Utah
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Shannon K. McWeeney
Shannon K. McWeeney Oregon Health & Science University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Richard A. Larson
Richard A. Larson University of Chicago
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Jerald P. Radich
Jerald P. Radich Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens a wide range of healthcare careers beyond traditional medical school. Many in-demand roles can be accessed through affordable, flexible online programs, making them ideal options for both recent graduates and working professionals.

If you are interested in pharmacy, a pharmacy school online can help you earn a respected degree without interrupting your current commitments. For those drawn to healthcare data, rhit programs online provide a pathway to a career in health information management.

Careers in medical administration are also accessible. A medical coding certification online can open doors in billing, record-keeping, and practice management—all critical to healthcare operations.

Nursing offers several growth opportunities, and the cheapest fnp programs online allow you to become a family nurse practitioner remotely, often at a fraction of on-campus costs. These online options make it easier than ever to enter and advance in the healthcare field, supporting a variety of rewarding career trajectories.

Best Scientists Citing Brian J. Druker

Trending Scientists